181473-92-7

Usage

Uses

Used in Pharmaceutical Industry:
(5-chloro-2-methoxyphenyl)methanamine is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to be incorporated into the molecular structures of active drug compounds. Its unique properties allow for the development of new medications with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, (5-chloro-2-methoxyphenyl)methanamine serves as a building block for the creation of various agrochemicals, such as pesticides and herbicides. Its chemical structure contributes to the effectiveness of these products in controlling pests and promoting crop health.
Used in Dye and Pigment Industry:
(5-chloro-2-methoxyphenyl)methanamine is utilized as a precursor in the production of dyes and pigments due to its ability to form colored compounds. Its unique properties enable the creation of a wide range of colors for use in various applications, including textiles, plastics, and printing inks.
Used in Fine Chemicals Industry:
As a versatile intermediate, (5-chloro-2-methoxyphenyl)methanamine is employed in the synthesis of various fine chemicals, such as fragrances, flavorings, and other specialty chemicals. Its unique structure allows for the development of novel compounds with specific properties for use in diverse industries.

Upstream product

• 55877-79-7 2-methoxy-5-chlorobenzonitrile 

Downstream Products

• 1394153-56-0 N-[(5-chloro-2-methoxyphenyl)methyl]-N'-(3-nitrophenyl)thiourea 
• 1394153-55-9 N-[(5-chloro-2-methoxyphenyl)methyl]-N'-(4-nitrophenyl)thiourea 
• 894770-21-9 N-[(5-chloro-2-methoxyphenyl)methyl]methanesulfonamide 
• 793695-66-6 (1'S,2'R,3'S,4'R,5'S)-4'-[6-(5-chloro-2-methoxybenzylamino)-2-chloropurin-9-yl]-2',3'-O-isopropylidenebicyclo[3.1.0]haxane-1'-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

MODULATORS OF TMEM16A FOR TREATING RESPIRATORY DISEASE

Compounds of general formula (I), which are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A. wherein A is defined as Formula.

2-substituted parazoleamino-4-substituted amino-5-pyrimidine formamide compound, composition and application thereof

The invention relates to a series of new compounds as a JAK inhibitor, as well as compositions and applications thereof, and particularly provides a series of compounds (I) that have a strong JAK inhibiting activity, or stereisomers, geometrical isomers, tautomers, pharmaceutically acceptable salts, prodrugs, metabolites, isotope derivatives, and solvates, as well as medicine compositions comprising such compounds. The invention also discloses applications of the compounds or the medicine compositions in preparation of a medicine, which is used for treatment of autoimmune diseases or cancer.

N-Aryl-N'-(chroman-4-yl)ureas and thioureas display in vitro anticancer activity and selectivity on apoptosis-resistant glioblastoma cells: Screening, synthesis of simplified derivatives, and structure-activity relationship analysis

A series of chroman derivatives previously reported as potassium channel openers, as well as some newly synthesized simplified structures, were examined for their in vitro effects on the growth of three human high-grade glioma cell lines: U373, T98G, and Hs683. Significant in vitro growth inhibitory activity was observed with 2,2-dimethylchroman-type nitro-substituted phenylthioureas, such as compounds 4o and 4p. Interestingly, most tested phenylureas were found to be slightly less active, but more cell selective (normal versus tumor glial cells, such as 3d, 3e, and 3g), thus less toxic, than the corresponding phenylthioureas. No significant differences were observed in terms of chroman-derivative-induced growth inhibitory effects between glioma cells sensitive to pro-apoptotic stimuli (Hs683 glioma cells) and glioma cells associated with various levels of resistance to pro-apoptotic stimuli (U373 and T98G glioma cells), a feature that suggests non-apoptotic-mediated growth inhibition. Flow cytometry analyses confirmed the absence of pro-apoptotic effects for phenylthioureas and phenylureas when analyzed in U373 glioma cells and demonstrated U373 cell cycle arrest in the G0/G1 phase. Computer-assisted phase-contrast videomicroscopy revealed that 3d and 3g displayed cytostatic effects, while 3e displayed cytotoxic ones. As a result, this work identified phenylurea-type 2,2-dimethylchromans as a new class of antitumor agents to be further explored for an innovative therapeutic approach for high-grade glioma and/or for a possible new mechanism of action.

Compounds for the treatment of ischemia

A3 agonists, methods of using such A3 agonists and pharmaceutical compositions containing such A3 agonists. The A3 agonists are useful for the reduction of tissue damage resulting from tissue ischemia or hypoxia